Phase 2 Schizophrenia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People of any gender between 18 and 35 years old.
• People who have been diagnosed with a Schizophrenia Spectrum Disorder (a type of psychotic illness) lasting at least six months, confirmed using a standard psychiatric interview tool.
• People whose symptom scores on a standard rating scale (called the PANSS) meet a certain level of severity, including having at least two notably elevated positive symptoms (such as hallucinations or delusions).
• People who had normal school performance up to at least age 15 and had no psychiatric symptoms before that age.
• People who are able to give their agreement to take part in the study and complete the required tests.

Who may not be able to join:

• People whose antipsychotic medication dose was changed less than two weeks before the first assessment visit.
• People who have been treated with immune-suppressing medications (other than standard pain relief or fever-reducing medicines) in the six months before joining the trial.
• People who received a live vaccine less than four weeks before the study infusion, or a non-live vaccine less than two weeks before the infusion.
• People who have an active infection, or a history of recurring or long-term infections such as hepatitis B or C, HIV, syphilis, tuberculosis, or a condition called PML.
• People with a history of brain tumour, stroke, severe head injury, or multiple sclerosis.
• People with active cancer, a metabolic brain condition, or severe heart or kidney disease.
• People whose psychosis the lead researcher believes is caused by substance use or a metabolic disorder.
• People who are pregnant or breastfeeding.
• People who would need ongoing steroid or immune-suppressing treatment throughout the study period.
• People who have a current or past history of a condition where the immune system does not work properly (primary or secondary immunodeficiency).
• People who have had a severe allergic or anaphylactic reaction to a type of laboratory-made antibody treatment (called humanized or murine monoclonal antibodies).
• People for whom steroid medications (taken by mouth or by drip) are not suitable or not tolerated.

Important: Always verify eligibility with the trial site directly before applying.